Skip to content

Philip Deitiker, PhD

Senior Scientific Collaborator, Institute for Allergic Inflammation

Biochemist | Immunogenetics Researcher | Molecular Inflammation Scientist

Dr. Philip Deitiker portrait

Dr. Philip R. Deitiker is a biochemist whose work bridges molecular biology, immunogenetics, and the evolving science of chronic inflammation. He earned his PhD in Biochemistry and previously served in the Department of Biochemistry and Molecular Biology at Baylor College of Medicine in Houston, Texas. His academic and research background brings a complementary scientific foundation to the Institute for Allergic Inflammation's mission of understanding systemic allergic inflammation and its downstream effects across multiple organ systems.

With expertise spanning protein chemistry and immune pathway analysis, Dr. Deitiker has contributed to diverse areas of biological research. His early work examined the molecular architecture of muscle thick filaments in C. elegans, establishing a strong foundation in protein assembly and structure-function relationships. He later expanded into immunology, studying the role of specific HLA molecules in autoimmune predisposition, antigen recognition, and immune tolerance. His peer-reviewed publications include studies on antigen-specific T-cell responses, autoimmunity-associated HLA variation, and immune recognition of therapeutic botulinum neurotoxin type A.

Dr. Deitiker now serves as a key scientific collaborator with the Institute, working alongside Dr. Doanh Nguyen on research exploring the progression of chronic allergic inflammation into systemic disease. Together, and the emergence of nascent autoimmunity. His expertise includes investigating inflammatory load biomarkers, immune activation pathways, and the molecular mechanisms linking airway inflammation to systemic epithelial dysfunction. His integrative biochemical perspective strengthens the Institute's efforts to develop objective, laboratory-based tools for early detection and monitoring of disease activity.

Through his ongoing contributions, Dr. Deitiker plays a central role in advancing the Institute's research agenda, helping illuminate how chronic allergic inflammation propagates across organ systems and identifying new molecular pathways that could guide early intervention and immune stabilization.

Selected Publication

  • Nguyen D, Deitiker P., Sustained control of recalcitrant chronic spontaneous urticaria after initiation of inflammatory airway diseases treatment: two case reports. J Med Case Rep 2024 Dec 23;18(1):13. PubMed ID: PMCID: PMC10893739

  • Deitiker P, Atassi MZ. Non-MHC genes linked to autoimmune disease. Crit Rev Immunol. 2012;32(3):193-285. doi:10.1615/critrevimmunol.v32.i3.10. PubMed

  • Deitiker PR, Oshima M, Smith RG, Mosier DR, Atassi MZ. Subtle differences in HLA DQ haplotype-associated presentation of AChR α-chain peptides may suffice to mediate myasthenia gravis. Autoimmunity. 2006;39(4):277-288. doi:10.1080/08916930600738581. PubMed

  • Oshima M, Deitiker PR, Smith RG, Mosier DR, Atassi MZ. Responses in vitro of peripheral blood lymphocytes from patients with myasthenia gravis to stimulation with human acetylcholine receptor α-chain peptides: analysis in relation to age, thymic abnormality, and ethnicity. Hum Immunol. 2005;66(1):32-42. doi:10.1016/j.humimm.2004.09.015. PubMed

  • Oshima M, Maki Ohtani, Deitiker PR, Smith RG, Mosier DR, Atassi MZ. Suppression by mAbs against DQB1 peptides of in vitro proliferation of AChR-specific T cells from myasthenia gravis patients. Autoimmunity. 2005;38(2):161-169. doi:10.1080/08916930500050491. PubMed

  • Oshima M, Maruta T, Ohtani M, Deitiker P, Mosier DR, Atassi MZ. Vaccination with a MHC II peptide in Alum and inactive pertussis strongly ameliorates clinical MG in C57BL/6 mice. J Neuroimmunol. 2006;171(1-2):8-16. doi:10.1016/j.jneuroim.2005.09.015. PubMed

  • Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from patients with focal hand dystonia and/or spasmodic torticollis and benign essential tremor disorder patients. J Neuroimmunol. 2011;237(1-2):66-72. doi:10.1016/j.jneuroim.2011.06.005. PubMed

  • Oshima M, Deitiker PR, Jankovic J, Duane DD, Aoki KR, Atassi MZ. Human T-cell responses to botulinum neurotoxin: responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011;240-241:121-128. doi:10.1016/j.jneuroim.2011.10.005. PubMed

  • Deitiker P, Atassi MZ. MHC Genes Linked to Autoimmune Disease. Crit Rev Immunol. 2015;35(3):203-251. doi:10.1615/critrevimmunol.2015014510